Allergan Inc (AGN) 189.44 $AGN
Sanofi Beats on Q3 Earnings but Lantus Outlook Disappoints - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 1:45PM CDT
Sanofi reported third-quarter 2014 business earnings of 97 cents per ADS, 3 cents above the Zacks Consensus Estimate.
AGN: 189.44 (+2.67), NVO: 46.21 (+2.70), ABBV: 61.18 (+1.20), SNY: 45.70 (+0.48)
Charles River (CRL) Beats on Q3 Earnings, Guidance Upped - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 11:30AM CDT
Charles River Laboratories (CRL) reported third-quarter 2014 earnings (excluding special items) of 86 cents per share.
AGN: 189.44 (+2.67), ABBV: 61.18 (+1.20), BMY: 58.98 (+4.82), CRL: 62.81 (-1.66)
Shares of AGN Up 11.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Oct 30, 9:25AM CDT
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on September 11th, 2014 at $167.11. In approximately 2 months, Allergan has returned 11.79% as of today's recent price of $186.80.
AGN: 189.44 (+2.67)
Botulinum Toxin - Global Strategic Business Report 2014-2020
M2 - Thu Oct 30, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qw6vx2/botulinum_toxin) has announced the addition of the "Botulinum Toxin - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. This report analyzes the worldwide markets for Botulinum Toxin in US$ Million by the following Segments: - Cosmetic Applications - Therapeutic Applications The report profiles 19 companies including many key and niche players such as: - Allergan, Inc. - Ipsen Group - Medy-Tox Incorporated - Mentor Corporation - Merz Pharma GmbH & Co. KGaA - Metabiologics, Inc. - Revance Therapeutics, Inc. - US WorldMeds Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Competition 3. Market Trends & Issues 4. Product/Industry Dynamics 5. Product Overview 6. Research Breakthroughs 7. Product Introductions/Approvals 8. Recent Industry Activity 9. Focus On Select Global Players 10. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 19 (including Divisions/Subsidiaries - 23) - The United States (9) - Japan (2) - Europe (6) - -France (1) - - Germany (1) - - The United Kingdom (3) - - Rest of Europe (1) - Asia-Pacific (Excluding Japan) (6) For more information visit http://www.researchandmarkets.com/research/qw...inum_toxin
AGN: 189.44 (+2.67), RVNC: 19.62 (+0.31)
eVivite.com Continues to Sell VIVITÉ(R) Products After Allergan Announces Its Discontinuation
PRWeb - Thu Oct 30, 2:01AM CDT
After Allergan's announcement that they will be discontinuing their VIVITÉ(R) skin care product line, online supplier eVivite.com announced their plans to resume sales as long as products are available. As of March 2014 Allergen had already halted production of the products, and they informed retailers that they would only be distributing what had already been produced. The final shipments to suppliers are expected to occur sometime in June.
AGN: 189.44 (+2.67)
San Marcos Dentist, Jeffrey Allred, Certified by Allergan to Provide Botox to Patients Having Dental Problems
PRWeb - Wed Oct 29, 2:11PM CDT
Jeffrey Allred DDS at Allred Dental in San Marcos, CA is now providing therapeutic Botox injections. Botox till recently was known to be used mainly for cosmetic purposes, but now it is used in dentistry as well.
AGN: 189.44 (+2.67)
Express Scripts Reports In-Line Q3 Earnings, Narrows View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:26PM CDT
Express Scripts Holding Company posted third-quarter 2014 earnings per share (excluding special items) of $1.29, in line with the Zacks Consensus Estimate.
AGN: 189.44 (+2.67), ESRX: 75.54 (+1.51), CAH: 78.19 (+0.11), UNH: 93.88 (+0.92), CRL: 62.81 (-1.66)
Novartis (NVS) Beats on Q3 Earnings, Revenues; Keeps View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:04PM CDT
Novartis reported core earnings per share came in at $1.37, up 10% from the year-ago period and beat the Zacks Consensus Estimate of $1.29.
AGN: 189.44 (+2.67), LLY: 66.80 (+1.31), GSK: 45.14 (+0.06), NVS: 91.95 (+0.64)
3 Health Care Picks To Beat Earnings - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 11:09AM CDT
These stocks are well positioned in today's market environment.
ENDP: 66.29 (+0.64), VRX: 131.51 (+1.75), ACT: 243.21 (+4.43), AMGN: 161.58 (+2.70), TKMR: 16.94 (+0.07), GSK: 45.14 (+0.06), AGN: 189.44 (+2.67), JNJ: 107.04 (+1.48), SHPG: 199.42 (+2.97), MRK: 57.31 (+1.11), INFI: 13.81 (+0.23), ABBV: 61.18 (+1.20), KPTI: 40.05 (+0.24)
McKesson Beats on Q2 Earnings, Revenues; Keeps Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 10:14AM CDT
McKesson Corporation (MCK) reported fiscal second-quarter 2015 (ended Sep 30, 2014) earnings of $2.79 per share, comfortably beating the Zacks Consensus Estimate of $2.74
AGN: 189.44 (+2.67), MCK: 203.48 (+5.03), CAH: 78.19 (+0.11), CRL: 62.81 (-1.66)
Allergan Canada Launches a 3D JUVEDERM(R) Visualization iPad App Powered by ModiFace
Marketwired - Wed Oct 29, 8:02AM CDT
Allergan Canada, in partnership with ModiFace Inc., is delighted to announce the launch of the Juvederm(R) Visualizer 3D iPad application. For the first time, users can create a 3D image of the potential results of Juvederm(R) facial filler showing all angles of their face. This new application enables you to simulate the effects of Juvederm(R) facial filler by creating a 3D image of your face that can be rotated and viewed from all angles. You can then apply over 10 Juvederm(R) treatment effects such as smoothing laugh lines and enhancing cheeks and lips.
AGN: 189.44 (+2.67)
Gilead Beats on Q3 Earnings, Sovaldi Sales Fall Sequentially - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:00AM CDT
Gilead Sciences, Inc. reported third-quarter earnings (including stock-based compensation expenses) of $1.79 per share.
AGN: 189.44 (+2.67), GILD: 114.22 (+3.50), MRK: 57.31 (+1.11), ABBV: 61.18 (+1.20)
Pfizer Q3 Earnings Top Estimates Despite Generic Pressure - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 3:10PM CDT
Pfizer's (PFE) third quarter earnings and revenues were better-than-expected despite the presence of generic pressure.
AGN: 189.44 (+2.67), BIIB: 321.00 (+5.94), PFE: 29.84 (+0.35), ABBV: 61.18 (+1.20)
Allergan (AGN) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Tue Oct 28, 1:44PM CDT
The following Allergan (AGN) conference call took place on October 27, 2014, 09:00 AM ET. This is a transcript of that earnings call:
AGN: 189.44 (+2.67)
Stock Market News for October 28, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 9:10AM CDT
Benchmarks were little changed on Monday as investors took a breather following last week’s sharp gains
MU: 31.82 (-0.46), VRX: 131.51 (+1.75), NBR: 17.50 (-0.42), HAL: 53.92 (-0.50), XOM: 94.45 (-0.14), BRCD: 10.49 (-0.13), SLB: 97.62 (+0.21), AGN: 189.44 (+2.67), CHK: 21.35 (-0.24), MRK: 57.31 (+1.11), EOG: 92.22 (-0.91), DD: 67.66 (+0.86), PX: 122.67 (+0.06), CVX: 117.20 (+0.06), VZ: 49.90 (+0.07), DOW: 48.25 (+0.87), ECL: 108.35 (+0.19)
Global Postherpetic Neuralgia Clinical Trials Review, H2, 2014
M2 - Tue Oct 28, 5:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkgchq/postherpetic) has announced the addition of the "Postherpetic Neuralgia Global Clinical Trials Review, H2, 2014" report to their offering. Postherpetic Neuralgia Global Clinical Trials Review, H2, 2014" provides data on the Postherpetic Neuralgia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Postherpetic Neuralgia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Postherpetic Neuralgia. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Clinical Trial Overview of Top Companies - Pfizer Inc. - NeurogesX, Inc. - Spinifex Pharmaceuticals Pty Limited - Merck & Co., Inc. - UCB S.A. - GlaxoSmithKline plc - Allergan, Inc. - Depomed, Inc. - Daiichi Sankyo Company, Limited - Astellas Pharma Inc. Clinical Trial Overview of Top Institutes / Government - University of California, San Francisco - Hopital Ambroise Pare - Shanghai Sixth People's Hospital - Xinhua Hospital - University of Wisconsin Madison - Nucleus Network - Shiraz University of Medical Sciences - George Washington University - Loma Linda University - University of Sao Paulo For more information visit http://www.researchandmarkets.com/research/nk...stherpetic
AGN: 189.44 (+2.67), PFE: 29.84 (+0.35), MRK: 57.31 (+1.11), DEPO: 15.34 (+0.04), GSK: 45.14 (+0.06)
Jim Cramer's Top Stock Picks: CME AGN UNFI SYK
at The Street - Tue Oct 28, 5:00AM CDT
Cramer says Allergan doesn't need a hostile takeover to unlock shareholder value while Stryker is at the top of its game.
AGN: 189.44 (+2.67), CME: 81.56 (-0.27), UNFI: 68.02 (+1.87), SYK: 87.04 (+0.36)
Jim Cramer's 'Mad Money' Recap: How Do You Make Money in a Clueless Market?
at The Street - Mon Oct 27, 6:50PM CDT
In order to truly understand what's going on with the markets you must realize the hedge funds trump everything, Cramer says.
AGN: 189.44 (+2.67), VRX: 131.51 (+1.75), UNFI: 68.02 (+1.87), AZO: 551.46 (+1.42), CMG: 639.68 (-0.18), CFX: 52.48 (-0.04), VSLR: 13.75 (+0.03), IRBT: 35.11 (+0.40), SYK: 87.04 (+0.36)
Allergan lifts outlook
at Investor's Business Daily - Mon Oct 27, 5:49PM CDT
The specialty drugmaker's Q3 EPS ex-items rose 45% to $1.78, beating views by 10 cents. Sales rose 17% to $1.8 bil, slightly above expectations. Allergan (AGN) sees Q4 EPS of $1.80-$1.83, up from $1.35 in '13 and above the $1.76 consensus. Allergan...
AGN: 189.44 (+2.67), VRX: 131.51 (+1.75)
AstraZeneca's Lynparza a Step Closer to European Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 4:41PM CDT
The CHMP gave a positive opinion in favour of approving AstraZeneca's (AZN) Lynparza.
AGN: 189.44 (+2.67), CLVS: 59.16 (+1.92), AZN: 72.60 (+1.07), REGN: 392.80 (+5.10)
Sanofi Beats on Q3 Earnings but Lantus Outlook Disappoints - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 1:45PM CDT
Sanofi reported third-quarter 2014 business earnings of 97 cents per ADS, 3 cents above the Zacks Consensus Estimate.
AGN: 189.44 (+2.67), NVO: 46.21 (+2.70), ABBV: 61.18 (+1.20), SNY: 45.70 (+0.48)
Charles River (CRL) Beats on Q3 Earnings, Guidance Upped - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 11:30AM CDT
Charles River Laboratories (CRL) reported third-quarter 2014 earnings (excluding special items) of 86 cents per share.
AGN: 189.44 (+2.67), ABBV: 61.18 (+1.20), BMY: 58.98 (+4.82), CRL: 62.81 (-1.66)
Shares of AGN Up 11.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Oct 30, 9:25AM CDT
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on September 11th, 2014 at $167.11. In approximately 2 months, Allergan has returned 11.79% as of today's recent price of $186.80.
AGN: 189.44 (+2.67)
Botulinum Toxin - Global Strategic Business Report 2014-2020
M2 - Thu Oct 30, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qw6vx2/botulinum_toxin) has announced the addition of the "Botulinum Toxin - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. This report analyzes the worldwide markets for Botulinum Toxin in US$ Million by the following Segments: - Cosmetic Applications - Therapeutic Applications The report profiles 19 companies including many key and niche players such as: - Allergan, Inc. - Ipsen Group - Medy-Tox Incorporated - Mentor Corporation - Merz Pharma GmbH & Co. KGaA - Metabiologics, Inc. - Revance Therapeutics, Inc. - US WorldMeds Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Competition 3. Market Trends & Issues 4. Product/Industry Dynamics 5. Product Overview 6. Research Breakthroughs 7. Product Introductions/Approvals 8. Recent Industry Activity 9. Focus On Select Global Players 10. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 19 (including Divisions/Subsidiaries - 23) - The United States (9) - Japan (2) - Europe (6) - -France (1) - - Germany (1) - - The United Kingdom (3) - - Rest of Europe (1) - Asia-Pacific (Excluding Japan) (6) For more information visit http://www.researchandmarkets.com/research/qw...inum_toxin
AGN: 189.44 (+2.67), RVNC: 19.62 (+0.31)
eVivite.com Continues to Sell VIVITÉ(R) Products After Allergan Announces Its Discontinuation
PRWeb - Thu Oct 30, 2:01AM CDT
After Allergan's announcement that they will be discontinuing their VIVITÉ(R) skin care product line, online supplier eVivite.com announced their plans to resume sales as long as products are available. As of March 2014 Allergen had already halted production of the products, and they informed retailers that they would only be distributing what had already been produced. The final shipments to suppliers are expected to occur sometime in June.
AGN: 189.44 (+2.67)
San Marcos Dentist, Jeffrey Allred, Certified by Allergan to Provide Botox to Patients Having Dental Problems
PRWeb - Wed Oct 29, 2:11PM CDT
Jeffrey Allred DDS at Allred Dental in San Marcos, CA is now providing therapeutic Botox injections. Botox till recently was known to be used mainly for cosmetic purposes, but now it is used in dentistry as well.
AGN: 189.44 (+2.67)
Express Scripts Reports In-Line Q3 Earnings, Narrows View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:26PM CDT
Express Scripts Holding Company posted third-quarter 2014 earnings per share (excluding special items) of $1.29, in line with the Zacks Consensus Estimate.
AGN: 189.44 (+2.67), ESRX: 75.54 (+1.51), CAH: 78.19 (+0.11), UNH: 93.88 (+0.92), CRL: 62.81 (-1.66)
Novartis (NVS) Beats on Q3 Earnings, Revenues; Keeps View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:04PM CDT
Novartis reported core earnings per share came in at $1.37, up 10% from the year-ago period and beat the Zacks Consensus Estimate of $1.29.
AGN: 189.44 (+2.67), LLY: 66.80 (+1.31), GSK: 45.14 (+0.06), NVS: 91.95 (+0.64)
3 Health Care Picks To Beat Earnings - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 11:09AM CDT
These stocks are well positioned in today's market environment.
ENDP: 66.29 (+0.64), VRX: 131.51 (+1.75), ACT: 243.21 (+4.43), AMGN: 161.58 (+2.70), TKMR: 16.94 (+0.07), GSK: 45.14 (+0.06), AGN: 189.44 (+2.67), JNJ: 107.04 (+1.48), SHPG: 199.42 (+2.97), MRK: 57.31 (+1.11), INFI: 13.81 (+0.23), ABBV: 61.18 (+1.20), KPTI: 40.05 (+0.24)
McKesson Beats on Q2 Earnings, Revenues; Keeps Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 10:14AM CDT
McKesson Corporation (MCK) reported fiscal second-quarter 2015 (ended Sep 30, 2014) earnings of $2.79 per share, comfortably beating the Zacks Consensus Estimate of $2.74
AGN: 189.44 (+2.67), MCK: 203.48 (+5.03), CAH: 78.19 (+0.11), CRL: 62.81 (-1.66)
Allergan Canada Launches a 3D JUVEDERM(R) Visualization iPad App Powered by ModiFace
Marketwired - Wed Oct 29, 8:02AM CDT
Allergan Canada, in partnership with ModiFace Inc., is delighted to announce the launch of the Juvederm(R) Visualizer 3D iPad application. For the first time, users can create a 3D image of the potential results of Juvederm(R) facial filler showing all angles of their face. This new application enables you to simulate the effects of Juvederm(R) facial filler by creating a 3D image of your face that can be rotated and viewed from all angles. You can then apply over 10 Juvederm(R) treatment effects such as smoothing laugh lines and enhancing cheeks and lips.
AGN: 189.44 (+2.67)
Gilead Beats on Q3 Earnings, Sovaldi Sales Fall Sequentially - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:00AM CDT
Gilead Sciences, Inc. reported third-quarter earnings (including stock-based compensation expenses) of $1.79 per share.
AGN: 189.44 (+2.67), GILD: 114.22 (+3.50), MRK: 57.31 (+1.11), ABBV: 61.18 (+1.20)
Pfizer Q3 Earnings Top Estimates Despite Generic Pressure - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 3:10PM CDT
Pfizer's (PFE) third quarter earnings and revenues were better-than-expected despite the presence of generic pressure.
AGN: 189.44 (+2.67), BIIB: 321.00 (+5.94), PFE: 29.84 (+0.35), ABBV: 61.18 (+1.20)
Allergan (AGN) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Tue Oct 28, 1:44PM CDT
The following Allergan (AGN) conference call took place on October 27, 2014, 09:00 AM ET. This is a transcript of that earnings call:
AGN: 189.44 (+2.67)
Stock Market News for October 28, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 9:10AM CDT
Benchmarks were little changed on Monday as investors took a breather following last week’s sharp gains
MU: 31.82 (-0.46), VRX: 131.51 (+1.75), NBR: 17.50 (-0.42), HAL: 53.92 (-0.50), XOM: 94.45 (-0.14), BRCD: 10.49 (-0.13), SLB: 97.62 (+0.21), AGN: 189.44 (+2.67), CHK: 21.35 (-0.24), MRK: 57.31 (+1.11), EOG: 92.22 (-0.91), DD: 67.66 (+0.86), PX: 122.67 (+0.06), CVX: 117.20 (+0.06), VZ: 49.90 (+0.07), DOW: 48.25 (+0.87), ECL: 108.35 (+0.19)
Global Postherpetic Neuralgia Clinical Trials Review, H2, 2014
M2 - Tue Oct 28, 5:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkgchq/postherpetic) has announced the addition of the "Postherpetic Neuralgia Global Clinical Trials Review, H2, 2014" report to their offering. Postherpetic Neuralgia Global Clinical Trials Review, H2, 2014" provides data on the Postherpetic Neuralgia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Postherpetic Neuralgia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Postherpetic Neuralgia. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Clinical Trial Overview of Top Companies - Pfizer Inc. - NeurogesX, Inc. - Spinifex Pharmaceuticals Pty Limited - Merck & Co., Inc. - UCB S.A. - GlaxoSmithKline plc - Allergan, Inc. - Depomed, Inc. - Daiichi Sankyo Company, Limited - Astellas Pharma Inc. Clinical Trial Overview of Top Institutes / Government - University of California, San Francisco - Hopital Ambroise Pare - Shanghai Sixth People's Hospital - Xinhua Hospital - University of Wisconsin Madison - Nucleus Network - Shiraz University of Medical Sciences - George Washington University - Loma Linda University - University of Sao Paulo For more information visit http://www.researchandmarkets.com/research/nk...stherpetic
AGN: 189.44 (+2.67), PFE: 29.84 (+0.35), MRK: 57.31 (+1.11), DEPO: 15.34 (+0.04), GSK: 45.14 (+0.06)
Jim Cramer's Top Stock Picks: CME AGN UNFI SYK
at The Street - Tue Oct 28, 5:00AM CDT
Cramer says Allergan doesn't need a hostile takeover to unlock shareholder value while Stryker is at the top of its game.
AGN: 189.44 (+2.67), CME: 81.56 (-0.27), UNFI: 68.02 (+1.87), SYK: 87.04 (+0.36)
Jim Cramer's 'Mad Money' Recap: How Do You Make Money in a Clueless Market?
at The Street - Mon Oct 27, 6:50PM CDT
In order to truly understand what's going on with the markets you must realize the hedge funds trump everything, Cramer says.
AGN: 189.44 (+2.67), VRX: 131.51 (+1.75), UNFI: 68.02 (+1.87), AZO: 551.46 (+1.42), CMG: 639.68 (-0.18), CFX: 52.48 (-0.04), VSLR: 13.75 (+0.03), IRBT: 35.11 (+0.40), SYK: 87.04 (+0.36)
Allergan lifts outlook
at Investor's Business Daily - Mon Oct 27, 5:49PM CDT
The specialty drugmaker's Q3 EPS ex-items rose 45% to $1.78, beating views by 10 cents. Sales rose 17% to $1.8 bil, slightly above expectations. Allergan (AGN) sees Q4 EPS of $1.80-$1.83, up from $1.35 in '13 and above the $1.76 consensus. Allergan...
AGN: 189.44 (+2.67), VRX: 131.51 (+1.75)
AstraZeneca's Lynparza a Step Closer to European Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 4:41PM CDT
The CHMP gave a positive opinion in favour of approving AstraZeneca's (AZN) Lynparza.
AGN: 189.44 (+2.67), CLVS: 59.16 (+1.92), AZN: 72.60 (+1.07), REGN: 392.80 (+5.10)
